ISSN: 2455-1414 Open Access Journal of Clinical Research and Ophthalmology Clinical Group

Journal of Clinical Research and Ophthalmology

    Abstract

    Open Access Editorial Article ID: JCRO-3-126

    A Brief Editorial on Clinical Presentation and Treatment of Radiation Retinopathy Following Plaque Brachytherapy of Choroidal Melanoma

    Kiran Turaka and Aruna Turaka*

    Treatment of choroidal melanoma with radiation plaque brachytherapy (Iodine, (I125) avoids enucleation, salvages the globe, preserves the vision, achieves better local tumor control and prevents metastasis [1,2]. However, it can lead to complications such as keratitis, iris neovascularisation, cataract, radiation optic neuropathy, retinopathy, maculopathy and vitreous hemorrhage. Radiation retinopathy (RR) is one of the expected, common complications following external beam radiation, plaque brachytherapy of choridal melanoma, retinoblastoma, choroidal metastasis and orbital tumors.1,2 The common risk factors in the development of RR are posterior choroidal melanoma nearer to the fovea (< 3 mm from fovea), large choroidal tumors (base > 10mm), tumors limited to the choroid with no anterior uveal involvement, high radiation dose, use of radioisotope Iridium (Ir192) over I125, co-existing diabetes mellitus, hypertension, and use of radiosensitisers (such as chemotherapy) [1-3]. The severity and incidence of radiation retinopathy depends on size and location of the tumor, type of radiation used, method of delivery, total radiation dose and the fractionation scale.

    Keywords: Aflibercept; Anti-VEGF therapy; Laser Photocoagulation; Radiation Retinopathy; Ranibizumab

    Published on: Jan 6, 2016 Pages: 1-2

    Full Text PDF Full Text HTML DOI: 10.17352/2455-1414.000026
    Get Citation Base Search Scilit OAI-PMH ResearchGate SciForum CrossMark

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on JCRO